A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I
Launched by BRISTOL-MYERS SQUIBB · Jun 10, 2010
Trial Information
Current as of July 21, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Treatment-naive subjects with genotype 1 chronic HCV
- • HCV RNA ≥ 100,000 IU/mL at screening
- • Seronegative for HIV and HBsAg
- • Liver biopsy within prior 2 years demonstrating no cirrhosis
- Exclusion Criteria:
- • Any evidence of liver disease other than hepatitis C
- • Diagnosed or suspected hepatocellular carcinoma
- • Laboratory values: neutrophil count \< 1500 cells/μL, platelet count \< 90,000/μL; Hemoglobin ≤ 12 g/dL (120g/L) for women and ≤ 13 g/dL (130 g/L) for men
- • Cirrhosis
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Washington, District Of Columbia, United States
Laurel, Maryland, United States
Orlando, Florida, United States
Newport News, Virginia, United States
Coronado, California, United States
San Diego, California, United States
Bradenton, Florida, United States
Tamarac, Florida, United States
Mareitta, Georgia, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials